Combined Active Treatment in Type 2 Diabetes With NASH
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The aim of this multicentre, prospective, placebo-controlled, double-blind, randomized, 3-arm
parallel group, interventional study is to assess for the first time the effects of either a
combined therapy with the antihyperglycemic drugs semaglutide and empagliflozin or
empagliflozin monotherapy compared to placebo as potential treatments for non-alcoholic
steatohepatitis (NASH) in patients with type 2 diabetes.
Phase:
Phase 4
Details
Lead Sponsor:
The Deutsche Diabetes Forschungsgesellschaft e.V.
Collaborators:
Boehringer Ingelheim Federal Ministry of Health, Germany German Center for Diabetes Research Ministry of Innovation, Science and Research in North Rhine-Westphalia Novo Nordisk A/S